Straits Times Index
3,322.08 -8.69 (-0.26%) S&P 500
5,357.01 +10.02 (+0.19%) Dow
38,843.74 +44.75 (+0.12%) Nasdaq
17,174.65 +41.53 (+0.24%) Bitcoin USD
70,021.26 +305.61 (+0.44%) CMC Crypto 200
1,450.58 +3.91 (+0.27%)
TEVA Jun 2024 13.500 put
| Previous close | 0.0200 |
| Open | 0.0100 |
| Bid | 0.0000 |
| Ask | 1.2700 |
| Strike | 13.50 |
| Expiry date | 2024-06-07 |
| Day's range | 0.0100 - 0.1500 |
| Contract range | N/A |
| Volume | |
| Open interest | 29 |
Business WireTeva to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
TEL AVIV, Israel, June 04, 2024--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will present at the Goldman Sachs 45th Annual Global Healthcare Conference on Tuesday, June 11, 2024. The presentation will begin at 8:00 A.M. Eastern Time.
ZacksTEVA Stock Rises 135% in a Year: What's Driving the Recovery?
TEVA expects its newer drugs, Austedo, Uzedy and Ajovy, as well as a stable generics business, to help revive top-line growth in future quarters.
Business WireNew Data Provide Schizophrenia Treatment Insights into Switching to UZEDY® (risperidone) Extended-Release Injectable Suspension from Invega Sustenna® (paliperidone palmitate)
TEL AVIV, Israel & PARSIPPANY, N.J., June 01, 2024--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the presentation of seven studies from its long-acting injectable (LAI) schizophrenia research program. Presentations include data informing clinical strategies for switching patients to UZEDY, an extended-release injectable suspension of risperidone for subcutaneous use every one or two months for the treatment of schizophrenia
